Literature DB >> 10923927

Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: pathogenetic and histogenetic implications.

C Ariatti1, D Vivenza, D Capello, A Migliazza, G Parvis, L Fassone, D Buonaiuto, F Savinelli, D Rossi, G Saglio, G Gaidano.   

Abstract

Common-variable immunodeficiency (CVI) patients develop non-Hodgkin's lymphomas (NHL), mainly B-lineage diffuse large-cell lymphomas (DLCL), with a high relative risk. The molecular pathogenesis of CVI-related NHL (CVI-NHL) is unknown. Here we aimed at providing a detailed molecular characterization of CVI-NHL. Rearrangements of BCL-6 were detected in two thirds of CVI-NHL cases examined. All 3 CVI-NHL also harbored point mutations of the BCL-6 5' noncoding regions, which constitute a marker of B-cell transit through the germinal center (GC). The number and molecular pattern of BCL-6 mutations in CVI-NHL were similar to that detected in DLCL of immunocompetent hosts and in DLCL arising in other immunodeficiency settings. Microsatellite instability occurred in one CVI-NHL devoid of a BCL-6 rearrangement. All CVI-NHL scored negative for genetic lesions of BCL-2, p53, c-MYC, REL as well as for viral infection by EBV and HHV-8. Overall, these data indicate that: similarly to other immunodeficiency-related NHL, involvement of BCL6 occurs frequently also in CVI-NHL; and because BCL-6 mutations are acquired by B cells during GC transit, their occurrence in CVI-NHL suggest that these lymphomas are histogenetically related to GC B cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923927     DOI: 10.1053/hupa.2000.7626

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.

Authors:  Avi Shvarts; Thijn R Brummelkamp; Ferenc Scheeren; Eugene Koh; George Q Daley; Hergen Spits; René Bernards
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

2.  Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease.

Authors:  Kim Vaiphei; Neeraj Kumari; Saroj-Kant Sinha; Usha Dutta; Birinder Nagi; Kusum Joshi; Kartar Singh
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 3.  Common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

4.  Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease.

Authors:  Daniela Capello; Gianluca Gaidano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

Review 5.  Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions.

Authors:  Helen Chapel; Charlotte Cunningham-Rundles
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

6.  High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency.

Authors:  Adina K Knight; Lin Radigan; Thomas Marron; Allison Langs; Li Zhang; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2007-06-07       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.